New evidence for treatment of pulmonary embolism, asymptomatic carotid stenosis, and CLTI led the way in 2025.

CREST-2 (clinicaltrials.gov number: NCT02089217) is a pair of parallel, actively recruiting procedural trials to prevent stroke comparing: 1) carotid endarterectomy (CEA) and intensive medical ...

MIAMI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, welcomes the ...

Adding stenting to intensive medical therapy significantly improves outcomes among patients with asymptomatic high-grade carotid stenosis compared with drug treatment alone, a bar not met by carotid ...

TEL AVIV, Israel, Feb. 28, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery ...

TEL AVIV, Israel and MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today congratulated ...

A low rate of periprocedural stroke/death with carotid stenting for both asymptomatic and symptomatic patients has been reported in a new registry study. The CREST-2 Registry study found that 30-day ...

Brott and colleagues will pursue that question in the CREST-2 trial, for which enrollment is underway. As many as 2,480 patients aged 35 years and older with asymptomatic carotid artery stenosis of at ...

Carotid artery stenting combined with medical therapy demonstrated a significantly lower stroke risk compared to intensive medical therapy alone in patients with severe asymptomatic carotid stenosis ...